Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more
Market Cap & Net Worth: Mezzion Pharma Co.Ltd (140410)
Mezzion Pharma Co.Ltd (KQ:140410) has a market capitalization of $520.65 Million (₩762.33 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #6393 globally and #123 in its home market, demonstrating a -29.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mezzion Pharma Co.Ltd's stock price ₩89200.00 by its total outstanding shares 8546310 (8.55 Million).
Mezzion Pharma Co.Ltd Market Cap History: 2015 to 2026
Mezzion Pharma Co.Ltd's market capitalization history from 2015 to 2026. Data shows growth from $53.60 Million to $520.65 Million (24.61% CAGR).
Index Memberships
Mezzion Pharma Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.76% | #19 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.76% | #19 of 1384 |
Weight: Mezzion Pharma Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mezzion Pharma Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mezzion Pharma Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Mezzion Pharma Co.Ltd's market cap is 0.02 times its annual revenue
0.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $53.60 Million | $14.93 Billion | $4.22 Billion | 0.00x | 0.01x |
| 2016 | $44.75 Million | $8.75 Billion | -$12.98 Billion | 0.01x | N/A |
| 2017 | $77.63 Million | $5.59 Billion | -$14.88 Billion | 0.01x | N/A |
| 2018 | $179.00 Million | $19.09 Billion | -$18.88 Billion | 0.01x | N/A |
| 2019 | $372.20 Million | $18.93 Billion | -$23.25 Billion | 0.02x | N/A |
| 2020 | $342.04 Million | $28.63 Billion | -$13.83 Billion | 0.01x | N/A |
| 2021 | $422.39 Million | $26.65 Billion | -$13.60 Billion | 0.02x | N/A |
| 2022 | $75.88 Million | $30.73 Billion | -$36.30 Billion | 0.00x | N/A |
| 2023 | $227.64 Million | $31.72 Billion | -$12.73 Billion | 0.01x | N/A |
| 2024 | $180.07 Million | $8.61 Billion | -$19.48 Billion | 0.02x | N/A |
Competitor Companies of 140410 by Market Capitalization
Companies near Mezzion Pharma Co.Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Mezzion Pharma Co.Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #3465 globally with a market cap of $3.69 Billion USD ( ₩5.41 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #7113 globally with a market cap of $1.05 Billion USD ( ₩1.54 Trillion KRW).
- Kolon Life Science Inc (KQ:102940): Ranked #12728 globally with a market cap of $306.22 Million USD ( ₩448.36 Billion KRW).
- DongKook Pharmaceutical Co. Ltd (KQ:086450): Ranked #12931 globally with a market cap of $294.94 Million USD ( ₩431.85 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #3465 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $3.69 Billion | ₩739000.00 |
| #7113 | ST Pharm Co.Ltd | KQ:237690 | $1.05 Billion | ₩153400.00 |
| #12728 | Kolon Life Science Inc | KQ:102940 | $306.22 Million | ₩61000.00 |
| #12931 | DongKook Pharmaceutical Co. Ltd | KQ:086450 | $294.94 Million | ₩18140.00 |
Mezzion Pharma Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Mezzion Pharma Co.Ltd's market cap moved from $53.60 Million to $ 520.65 Million, with a yearly change of 24.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩520.65 Million | -1.00% |
| 2025 | ₩525.90 Million | +192.06% |
| 2024 | ₩180.07 Million | -20.90% |
| 2023 | ₩227.64 Million | +200.00% |
| 2022 | ₩75.88 Million | -82.04% |
| 2021 | ₩422.39 Million | +23.49% |
| 2020 | ₩342.04 Million | -8.10% |
| 2019 | ₩372.20 Million | +107.93% |
| 2018 | ₩179.00 Million | +130.58% |
| 2017 | ₩77.63 Million | +73.48% |
| 2016 | ₩44.75 Million | -16.52% |
| 2015 | ₩53.60 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Mezzion Pharma Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $520.65 Million USD |
| MoneyControl | $520.65 Million USD |
| MarketWatch | $520.65 Million USD |
| marketcap.company | $520.65 Million USD |
| Reuters | $520.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.